Eli LillyLLY
A drugmaker whose medicines include Mounjaro and Zepbound for diabetes and weight loss, as well as treatments for cancer and Alzheimer’s disease.
By financial year
| Figure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Income | |||||
| Revenue | $28.3bn | $28.5bn | $34.1bn | $45.0bn | $65.2bn |
| Gross profit | $21.0bn | $21.9bn | $27.0bn | $36.6bn | $54.1bn |
| Net income | $5.6bn | $6.2bn | $5.2bn | $10.6bn | $20.6bn |
| Earnings per share (diluted) | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Cash flow | |||||
| Cash from operations | $7.4bn | $7.6bn | $4.2bn | $8.8bn | $16.8bn |
| Capital spending | $1.3bn | $1.9bn | $3.4bn | $5.1bn | $7.8bn |
| Free cash flow | $6.1bn | $5.7bn | $792m | $3.8bn | $9.0bn |
| Share buybacks | $1.3bn | $1.5bn | $750m | $2.5bn | $4.1bn |
| Balance sheet (at the end of the period) | |||||
| Cash and investments | $3.9bn | $2.2bn | $2.9bn | $3.4bn | $7.3bn |
| Total debt | $16.9bn | $16.2bn | $25.2bn | $33.6bn | $42.5bn |
| Net debt (debt less cash) | $13.0bn | $14.0bn | $22.3bn | $30.2bn | $35.2bn |
| Shareholders’ equity | $9.0bn | $10.6bn | $10.8bn | $14.3bn | $26.5bn |
| Shares (diluted average) | 912m | 905m | 903m | 904m | 899m |
By quarter
| Figure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | $13.5bn | $12.7bn | $15.6bn | $17.6bn | $19.3bn | $19.8bn | $23.0bn | $24.4bn |
| Gross profit | $11.1bn | $10.5bn | $13.1bn | $14.6bn | $15.9bn | $16.2bn | $19.7bn | $20.5bn |
| Net income | $4.4bn | $2.8bn | $5.7bn | $5.6bn | $6.6bn | $7.4bn | $7.1bn | $6.5bn |
| Earnings per share (diluted) | — | $3.06 | $6.29 | $6.21 | — | $8.26 | $7.94 | $7.22 |
| Cash flow | ||||||||
| Cash from operations | $2.5bn | $1.7bn | $3.1bn | $8.8bn | $3.2bn | $5.3bn | $10.7bn | $11.4bn |
| Capital spending | $1.5bn | $1.5bn | $1.7bn | $2.1bn | $2.5bn | $2.3bn | $2.9bn | $3.2bn |
| Free cash flow | $978m | $156m | $1.4bn | $6.7bn | $678m | $3.0bn | $7.8bn | $8.2bn |
| Share buybacks | $2.1bn | $1.2bn | $692m | $708m | $1.5bn | $2.4bn | $1.6bn | $377m |
| Balance sheet (at the end of the period) | ||||||||
| Cash and investments | $3.4bn | $3.2bn | $3.5bn | $9.9bn | $7.3bn | $5.3bn | $8.9bn | $4.9bn |
| Total debt | $33.6bn | $38.5bn | $39.9bn | $42.5bn | $42.5bn | $43.4bn | $54.9bn | $49.5bn |
| Net debt (debt less cash) | $30.2bn | $35.3bn | $36.4bn | $32.6bn | $35.2bn | $38.1bn | $46.0bn | $44.6bn |
| Shareholders’ equity | $14.3bn | $15.8bn | $18.3bn | $23.8bn | $26.5bn | $31.2bn | $33.9bn | $40.3bn |
| Shares (diluted average) | — | 901m | 900m | 899m | — | 896m | 894m | 893m |
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.